1. Home
  2. MOBI

as of 11-16-2026 3:59pm EST

$13.15
$0.00
0.00%
Stocks Health Care Medical/Dental Instruments Nasdaq

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.

Founded: 2007 Country:
United States
United States
Employees: N/A City: AUSTIN
Market Cap: 383.0M IPO Year: 2026
Target Price: $18.00 AVG Volume (30 days): 183.8K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.14 EPS Growth: N/A
52 Week Low/High: $8.03 - $15.19 Next Earning Date: 11-05-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 71.88% Revenue Growth (next year): 43.02%
P/E Ratio: -4.19 Index:
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered MOBI Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 16 hours ago

AI Recommendation

sell
Model Precision: 0.00%
0.00%
AI Precision

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Mobia Medical Inc. Common Stock (MOBI)

Leavitt Chase C.

SEE REMARKS

Buy
MOBI Sep 11, 2026

Avg Cost/Share

$10.30

Shares

2,000

Total Value

$20,600.00

Owned After

5,000

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K

Nov 5, 2026

0001193125-26-449807

EX-99.1

2 mobi-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Mobia Medical Reports Third Quarter 2026 Financial Results

Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance

Austin, Texas, November 5, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial results for the quarter ended September 30, 2026.

Third Quarter 2026 and Recent Highlights

• Reported revenue of $15.6 million, representing 73% growth over the prior year period

• Achieved gross margin of 83.2%

• Increased average active territories in the quarter to 40, compared to 22.5 in the prior year period

• Announced inclusion of paired VNS in the updated 2026 AHA Guideline for stroke recovery

• Increased full year 2026 revenue guidance to be in the range of $57.0 million to $57.5 million compared to prior range of $54.0 million to $56.0 million

“This quarter, we delivered our strongest results yet. Revenue growth of 73% reflects the strength of our commercial execution and the predictable nature of our patient funnel,” said Richard Foust, President and Chief Executive Officer of Mobia Medical. “Additionally, we were pleased to announce the inclusion of paired VNS in the updated AHA Stroke guidelines for 2026, serving as validation of our evidence-based approach to stroke recovery and further recognition of how Vivistim® Paired VNS™ Therapy can redefine what is possible for stroke survivors. With our continued commercial traction and expanding territory footprint we are making substantial progress in generating greater access and awareness for this profoundly underserved patient population.”

Third Quarter 2026 Financial Results

Revenue increased by 73%, to $15.6 million for the third quarter of 2026, compared to $9.0 million for the third quarter of 2025. The growth was driven by broader adoption of the Vivistim System and increased product unit sales.

Gross profit increased by 81%, to $13.0 million for the third quarter of 2026, compared to $7.2 million for the third quarter of 2025. Gross margin was 83.2% for the third quarter of 2026, compared to 79.6% for the third quarter of 2025. The increase was primarily due to lower freight and tariff costs as a percentage of revenue and lower inventory write-offs compared to the prior year period.

Operating expenses increased 71% to $31.5 million for the third quarter of 2026, compared to $18.4 million for the third quarter of 2025, reflecting continued investment in the Company’s commercial organization to support revenue growth. The increase was primarily driven by higher personnel-related expenses, including increased headcount and higher sales commissions, as well as $2.2 million in additional stock-based compensation expense. Operating expenses declined as a percentage of revenue.

Net loss was $17.3 million, or $0.52 per share for the third quarter of 2026, compared to a net loss of $11.4 million, or $13.31 per share for the third quarter of 2025. The year-over-year improvement in net loss per share primarily reflects the significant increase in weighted-average common shares outstanding following the Company’s IPO and the related conversion of its outstanding redeemable convertible preferred stock and convertible notes into common stock.

As of September 30, 2026, cash and cash equivalents totaled $160.7 million.

2026 Outlook

The Company now expects revenue for the full year 2026 to be in the range of $57.0 million to $57.5 million, representing growth of 78% to 79% over the full year 2025, compared to the prior range of $54.0 million to $56.0 million.

Conference Call and Webcast Details

The Company will host a conference call today, November 5, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter 2026 financial results. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast can also be accessed via the News & Events page of the investor section of Mobia Medical’s website.

About Mobia Medical, Inc.

Mobia Medical, Inc. is a medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim® Paired VNS™ System is the first and only clinically validated, FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Therapy with the Vivistim® Paired VNS™ System combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. Mobia Medical is mobilizing patients, providers, and care partners to establish a better way for

2026
Q2

Q2 2026 Earnings

8-K

Aug 11, 2026

0001193125-26-344666

Transcript text not available. View on SEC.gov →

Share on Social Networks: